CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 16 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03149029
NCT03149029Phase 2Active
CompareCT.gov

A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma

Massachusetts General Hospital·interventional·Posted May 11, 2017·Updated Apr 21, 2026

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab, Dabrafenib, and 1 other intervention for Metastatic Melanoma. Active but no longer recruiting, targeting 16 participants across 3 sites.

Detailed Summary

This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: * Pembrolizumab (Keytruda) * Trametinib (Mekinist) * Dabrafenib (Tafinlar)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Melanoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2Active
2018201920202021202220232024202520262027
First PostedMay 11, 2017
Enrollment StartNov 27, 2017
Primary CompletionDec 31, 2021
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 9.1 years ago

Interventions

Pembrolizumabdrug

Pembrolizumab is a type of antibody that inhibits the cancer cell growth

Dabrafenibdrug

Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating

Trametinibdrug

Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth